Synlogic stock.

Find out all the key statistics for Synlogic, Inc. (SYBX), including valuation measures, fiscal year financial statistics, trading record, share statistics and more.Starting us off today is Twist Biosciences. In brief, Twist is a leading name in the synthetic biology industry today. The company’s core work revolves around its proprietary DNA synthesis ...Presentations included full data from both the Phase 2 Synpheny-1 Study in phenylketonuria and Phase 1 Study for SYNB1353 as a potential treatment for homocystinuriaCAMBRIDGE, Mass., March 20 ...Nov 24, 2023 · Chardan Raises Price Target on Synlogic to $6 From $5.50 Reflecting Lower Cash Burns Due to Recent Downsizing, Keeps Buy Rating. Jun. 06. MT. SVB Securities Cuts Synlogic's Price Target to $4 From $8, Maintains Outperform Rating. May. 12. MT. HC Wainwright Lowers Synlogic's Price Target to $5 From $7, Buy Rating Kept. Synlogic Inc stock performance at a glance. Check Synlogic Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and …

Synlogic (NASDAQ:SYBX) is undoubtedly a potential 10X investment, judging by its numbers alone. Shares of SYBX stock trade at only 53 cents per share, while its target stock price is $7.17 .

Synlogic Stock (NASDAQ:SYBX), Quotes and News Summary benzinga.com - February 11 at 9:36 AM Get Synlogic News Delivered to You Automatically Sign up to receive the latest news and ratings for SYBX and its competitors with MarketBeat's FREE daily newsletter.Synlogic’s pipeline is fueled by its Synthetic Biotic platform, which applies precision engineering to well-characterized probiotics. This creates GI-restricted, oral medicines designed to consume or modify disease-specific metabolites – an approach well suited for diseases such as PKU and HCU, both inborn errors of metabolism, as well as others in …

Oct 3, 2023 · Founded in 2014 by MIT professors Jim Collins and Tim Lu, Synlogic combines synthetic biology, a form of precision biological engineering, with principles of traditional drug development to design medicines for diseases that are in need of new approaches. The result is a robust engine that can create these potential medicines, called Synthetic ... Find out all the key statistics for Synlogic, Inc. (SYBX), including valuation measures, fiscal year financial statistics, trading record, share statistics and more.Synlogic, Inc. (SYBX) is a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases. The stock price, news, quote and history of SYBX are available on Yahoo Finance. See the latest performance outlook, earnings date, dividend yield and more. Get the latest Synlogic, Inc. (SYBX) stock news and headlines to help you in your trading and investing decisions. May 13, 2023 · Synlogic Revenues and Earnings Beat Expectations. Revenue exceeded analyst estimates by 25%. Earnings per share (EPS) also surpassed analyst estimates by 1.1%. Looking ahead, revenue is forecast ...

May 9, 2023 · About Synlogic Synlogic is the leading company advancing therapeutics based on synthetic biology. Synlogic’s pipeline includes its lead program in phenylketonuria (PKU), which has demonstrated proof of concept with plans to start a pivotal, Phase 3 study in the first half of 2023, and additional novel drug candidates designed to treat ...

Mar 29, 2023 · Fourth Quarter 2022 Financial Results. As of December 31, 2022, Synlogic had cash, cash equivalents, and short-term marketable securities of $77.6 million. Revenue was $0.1 million for the three ...

- Synlogic Commences Trading on NASDAQ Capital Market under Ticker Symbol “SYBX” - Combined Company has Approximately $100 Million in Cash and Cash Equivalents Following Transaction Close - Company Strengthens Board of Directors with addition of Michael Powell, Ph.D., and Richard Shea. CAMBRIDGE, Mass. & AUSTIN, …Stocks trading online may seem like a great way to make money, but if you want to walk away with a profit rather than a big loss, you’ll want to take your time and learn the ins and outs of online investing first. This guide should help get...Fourth Quarter 2021 Financial Results. As of December 31, 2021, Synlogic had cash, cash equivalents, and marketable securities of $136.6 million. Revenue was $0.6 million for the three months ...Nov 9, 2023 · Synlogic is a biotechnology company that designs Synthetic Biotics, living probiotics that treat diseases with Synthetic Biotic pipeline. The web page provides stock quote, chart, news releases, events, and corporate documents of Synlogic, as well as investor resources and contact information. May 13, 2023 · Synlogic Revenues and Earnings Beat Expectations. Revenue exceeded analyst estimates by 25%. Earnings per share (EPS) also surpassed analyst estimates by 1.1%. Looking ahead, revenue is forecast ... View the latest Synlogic Inc. (SYBX) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Since its IPO on the Shenzhen stock exchange, its share price has gone up every day by the exact same amount. Baofeng Technologies is China’s best performing stock this year. Since its IPO on the Shenzhen stock exchange, its share price has...What is the target price for Synlogic (SYBX) stock? A. The latest price target for Synlogic ( NASDAQ: SYBX) was reported by Chardan Capital on Friday, August 11, 2023. The analyst firm set a price ... On average, Wall Street analysts predict. that Synlogic's share price could reach $82.50 by Aug 11, 2024. The average Synlogic stock price prediction forecasts a potential upside of 4,025% from the current SYBX share price of $2.00.CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to SYNB1934 for the treatment of phenylketonuria (PKU).Synlogic Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. ... Stocks whose Next Earnings Date falls within the next 7 days are highlighted in red. Annual Dividend & Yield: The indicated annual dividend rate and yield, calculated from the latest dividend. The dividend rate is ...

Founded in 2014 by MIT professors Jim Collins and Tim Lu, Synlogic combines synthetic biology, a form of precision biological engineering, with principles of traditional drug development to design medicines for diseases that are in need of new approaches. The result is a robust engine that can create these potential medicines, called Synthetic ...Synlogic is a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases in need of new treatment options ...

Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout.Mar 29, 2023 · Fourth Quarter 2022 Financial Results. As of December 31, 2022, Synlogic had cash, cash equivalents, and short-term marketable securities of $77.6 million. Revenue was $0.1 million for the three ... Over the past week, Wood has been accumulating shares of Verve Therapeutics (VERV-6.12%) for her firm's flagship growth stock fund, the ARK Innovation ETF (ARKK 0.43%), and the biotech-focused ARK ...View live Synlogic, Inc. chart to track its stock's price action. Find market predictions, SYBX financials and market news.Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout.Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout.

Synlogic was spun out of MIT and uses technology developed by Drs. Tim Lu and Jim Collins. Synlogic was founded in 2014 and became a public company via a reverse merger in 2017. The first ...

Fourth Quarter 2021 Financial Results. As of December 31, 2021, Synlogic had cash, cash equivalents, and marketable securities of $136.6 million. Revenue was $0.6 million for the three months ...

Synlogic enacted this reverse stock split to boost the price of its shares and avoid delisting. The company’s stock previously closed out trading at just 28 cents. That’s below the $1 minimum ...But Ginkgo simultaneously invested $80 million in Synlogic at a sizable premium to its stock price at the time. In effect, the money took a round trip, starting as cash in Ginkgo’s bank account ...Mar 20, 2023 · About Synlogic Synlogic is the leading company advancing therapeutics based on synthetic biology. Synlogic’s pipeline includes its lead program in phenylketonuria (PKU), which has demonstrated proof of concept with plans to start a pivotal, Phase 3 study in the first half of 2023, and additional novel drug candidates designed to treat ... Synlogic ( NASDAQ: SYBX) on Wednesday said it will implement a 1-for-15 reverse stock split of its common stock, effective September 27. The reverse stock split is primarily intended to bring the ...Founded in 2014 by MIT professors Jim Collins and Tim Lu, Synlogic combines synthetic biology, a form of precision biological engineering, with principles of traditional drug development to design medicines for diseases that are in need of new approaches. The result is a robust engine that can create these potential medicines, called Synthetic ...SYBX Stock Summary. SYNLOGIC INC's market capitalization of $11,982,884 is ahead of only 7.07% of US-listed equities. As for revenue growth, note that SYBX's revenue has grown -47.85% over the past 12 months; that beats the revenue growth of merely 5.27% of US companies in our set. In terms of volatility of its share price, SYBX is more ...Founded in 2014 by MIT professors Jim Collins and Tim Lu, Synlogic combines synthetic biology, a form of precision biological engineering, with principles of traditional drug development to design medicines for diseases that are in need of new approaches. The result is a robust engine that can create these potential medicines, called Synthetic ...Sep 22, 2021 · All shares of common stock to be sold in the offering are being sold by Synlogic. In addition, Synlogic has granted to the underwriter a 30-day option to purchase up to 2,250,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions. Synlogic, Inc. CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed ...The first big announcement that META stock fans will want to note is details on the Meta Quest 3. This is the company’s VR headset that offers 10x the number of pixels as the Meta Quest 2 for $500.A high-level overview of Synlogic, Inc. (SYBX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Since its IPO on the Shenzhen stock exchange, its share price has gone up every day by the exact same amount. Baofeng Technologies is China’s best performing stock this year. Since its IPO on the Shenzhen stock exchange, its share price has...

Complete Synlogic Inc. stock information by Barron's. View real-time SYBX stock price and news, along with industry-best analysis. Synlogic Inc SYBX Morningstar Rating Unlock Stock XNAS Rating as of Nov 17, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation Operating...According to Accountingbase.com, common stock is neither an asset nor a liability; it is considered equity. Equity is basically considered to mathematically be the difference between the total assets and total liabilities of a company.Instagram:https://instagram. best python courses for beginnerschase credit card besttell stocksthlcx Find the latest Synlogic, Inc. (SYBX) stock quote, history, news and other vital information to help you with your stock trading and investing.١٠‏/٠٦‏/٢٠٢١ ... ... Synlogic's stock price peaked above $50/share. In mid-May, however, the price was just a tenth of that, closing on May 24 at less than $4/share. tqqq share pricevwehx stock price Mirna Therapeutics Inc (ZB_23894470.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Mirna Therapeutics Inc | Nasdaq: | Nasdaq. ... Synlogic to Implement 1-for-15 Reverse Stock Split Sep. 28: MT Earnings Flash (SYBX) SYNLOGIC Posts Q2 Revenue $35,000 Aug. 10: MT Synlogic, …Synlogic (NASDAQ:SYBX) is another biotech company, this time promising to treat diseases with high unmet need. It is a synthetic biology company focused on harnessing the power of artificial ... quarters that are worth a lot of money Dec 1, 2023 · According to 2 stock analysts, the average 12-month stock price forecast for Synlogic stock is $82.5, which predicts an increase of 3,122.66%. The lowest target is $75 and the highest is $90. On average, analysts rate Synlogic stock as a strong buy. Fourth Quarter 2022 Financial Results. As of December 31, 2022, Synlogic had cash, cash equivalents, and short-term marketable securities of $77.6 million. Revenue was $0.1 million for the three ...Nov 24, 2023 · Chardan Raises Price Target on Synlogic to $6 From $5.50 Reflecting Lower Cash Burns Due to Recent Downsizing, Keeps Buy Rating. Jun. 06. MT. SVB Securities Cuts Synlogic's Price Target to $4 From $8, Maintains Outperform Rating. May. 12. MT. HC Wainwright Lowers Synlogic's Price Target to $5 From $7, Buy Rating Kept.